Clinical trials: Clarithromycin
Asthma
Chronic Bronchiolitis or Resistant Asthma?
Chronic Bronchiolitis or Resistant Asthma? Testing a way to diagnosis and treatment
- Trial name
- NCT00368342
- Testing
- Erythromycin, Azithromycin , Clarithromycin
- Sponsor
- Baqiyatallah Medical Sciences University
Healthy
Bioequivaelnce Study of Clarithromycin 250 mg/5 mL Powder for Oral Suspension Under Fed Conditions
To compare the single-dose oral bioavailability of clarithromycin 250 mg/5 mL powder for oral suspension of Ranbaxy Laboratories with Biaxin 250 mg/5 mL granules for oral suspension in healthy, adult, human, male subjects under…
- Trial name
- NCT00775372
- Testing
- Clarithromycin 250mg/5mL
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
Helicobacter Infections
Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication
Clarithromycin-based triple therapy containing a proton-pump inhibitor (PPI) twice daily, amoxicillin 1g twice daily, and clarithromycin 500 mg twice daily for 7 days is one of the standard firs-line therapy for Helicobacter…
- Trial name
- NCT00816140
- Testing
- Cravit based triple therapy, Klaricid based triple therapy
- Where
- Taiwan
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
H Pylori Infection, H Pylori Gastritis
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1
H. pylori is an infection of the stomach that can cause chronic gastritis, gastric cancer and peptic ulcer disease. The goal of this study is to screen people for this infection and offer treatment for those who test positive for…
- Conditions
- H Pylori Infection, H Pylori Gastritis, Gastric Cancer
- Trial name
- NCT07224035
- Testing
- PYTEST® 14C-Urea Breath Test, VOQUEZNA® Triple Pak®
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- University of Miami
Helicobacter Pylori Infection
Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy
Background：Helicobacter pylori infection is a well-established risk factor for peptic ulcer disease and gastric cancer. It's now a consensus of experts that H.pylori infection should be treated once it is recognized.
- Trial name
- NCT06156085
- Testing
- Vonoprazan and Amoxicillin, Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole
- Where
- Taiwan
- Volunteers
- 337 people
- Sponsor
- Fu Jen Catholic University Hospital
Helicobacter Pylori Infection
Vonoprazan-based Therapy Versus Standard Regimen for Helicobacter Pylori Infection Management
Appropriately, half of the global population is infected with H. pylori, and it is now recognized that it causes at least 95% of all gastric cancers. Currently, the main challenge in the field of H.
- Trial name
- NCT05614934
- Testing
- standard Clarithromycin triple therapy, Vonoprazan triple therapy, Vonoprazan dual therapy
- Where
- Egypt
- Volunteers
- 132 people
- Sponsor
- Alexandria University
Healthy
A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants
The purpose of this study is to assess the effects of strong cytochrome P450 (CYP) 3A4 inhibitors (Itraconazole and Clarithromycin), on pharmacokinetics (PK) (study of the way a drug enters and leaves the blood and tissues over…
- Trial name
- NCT02197884
- Testing
- JNJ-54861911, 25 mg, Itraconazole 200 mg, Clarithromycin 500 mg
- Where
- Belgium
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Stomach Ulcer
Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy
The purpose of this study is to evaluate the ulcer healing efficacy of rebamipide in comparison with omeprazole in Helicobacter pylori-positive gastric ulcer after eradication therapy.
- Trial name
- NCT00272467
- Testing
- Rebamipide, Omeprazole
- Where
- 7 sites in China, South Korea
- Volunteers
- 132 people
- Sponsor
- Korea Otsuka International Asia Arab
B-cell Malignancies
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
The primary objective of this study was to assess the steady-state zanubrutinib pharmacokinetics (PK) when co-administered with moderate and strong cytochrome P450 family 3 subfamily A (CYP3A) inhibitors.
- Trial name
- NCT04551963
- Testing
- Zanubrutinib, Fluconazole, Diltiazem
- Where
- 7 sites in Australia
- Volunteers
- 26 people
- Sponsor
- BeiGene
Helicobacter Infection
Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection
Traditionally, H pylori infection has been treated with conventional triple therapy. This includes amoxicillin, clarithromycin and a proton pump inhibitor all given daily for 10-14 days.
- Trial name
- NCT01723059
- Testing
- Standard Triple Therapy, Sequential Therapy
- Where
- United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Dallas VA Medical Center
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
RCT: Triple vs Sequential vs Concomitant Therapy H Pylori
Triple therapy (TT) comprising proton pump inhibitor (PPI), amoxicillin 1g and clarithromycin 500mg twice daily has long been considered one of the standard treatment for H.
- Trial name
- NCT02092506
- Testing
- 10 day triple therapy, 10 day sequential therapy, 10 day concomitant therapy
- Where
- Singapore
- Volunteers
- 462 people
- Sponsor
- Changi General Hospital
Lymphoma
Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma
The purpose of this study is to see if a treatment with Biaxin (clarithromycin) which is an antibiotic given by mouth for 3 months can delay the growth of your lymphoma or shrink the lymphoma.
- Trial name
- NCT00461084
- Testing
- BIAXIN (CLARITHROMYCIN)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy
Compare efficacy and safety of 10-day triple therapy (rabeprazole, clarithromycin and amoxicillin) plus N-acetylcystein versus 10-day concomitant therapy (rabeprazole, clarithromycin, amoxicillin and metronidazole) for…
- Trial name
- NCT01572597
- Testing
- 10RAC+acetylcystein, 10RAC+metronidazole
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection
Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
The goal of this clinical trial is to learn if a new combination antibiotic treatment (Arm D) works to treat a rare lung condition called mycobacterium abscessus pulmonary disease in people of any age and sex, when compared to…
- Conditions
- Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections, Non-Tuberculous Mycobacteria Pulmonary Disease
- Trial name
- FORMaT-EVOLVE (NCT07485010)
- Testing
- Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin
- Volunteers
- 300 people
- Sponsor
- The University of Queensland
Helicobacter Pylori Infection
Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection
The purpose of this study is to evaluate efficacy of a 14-day concomitant therapy for the third-line treatment of Helicobacter pylori infection, and whether it is safe while maintaining an ideal eradication rates.
- Trial name
- NCT05133193
- Testing
- three kinds of antibiotics
- Volunteers
- 60 people
- Sponsor
- Shandong University
Myeloma Multiple, Myeloma
Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
The purpose of this study is to determine the efficacy and safety of investigational combination therapy of Selinexor, Clarithromycin, Pomalidomide and Dexamethasone (ClaSPd) for patients with relapsed/refractory multiple…
- Conditions
- Myeloma Multiple, Myeloma, Refractory Multiple Myeloma
- Trial name
- ClaSPd (NCT04843579)
- Testing
- Selinexor, Clarithromycin, Pomalidomide
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Weill Medical College of Cornell University
HELICOBACTER PYLORI INFECTIONS, Rescue Therapy for Helicobacter Pylori
Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing
Helicobacter pylori(H. pylori, Hp) is a major etiological agent in chronic gastritis, peptic ulcer disease, gastric cancer, and gastric MALT lymphoma.
- Trial name
- NCT07533422
- Testing
- Personalized treatment based on the results of fecal antimicrobial resistance gene testing, Conventional Quadruple Therapy
- Volunteers
- 531 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Anovulation, Disorder Due Cytochrome P450 CYP2D6 Variant
Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene
Aim of the study is the clinical validation of the metabolism and the pharmakokinetic of Clomifen in correlation to CYP2D6 and inhibition of CYP3A4.
- Conditions
- Anovulation, Disorder Due Cytochrome P450 CYP2D6 Variant, Cytochrome P450 CYP3A Enzyme Deficiency
- Trial name
- NCT01289756
- Testing
- Clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Helicobacter Pylori Infection
Probiotics in the Reduction of Adverse Effects and Dysbiosis of H. Pylori Eradication
The investigators aimed to assess the effect of probiotic supplementation with Vigiis 101-LAB during H. pylori eradication therapy with 14-day sequential therapy in the reduction of adverse effects and the restoration of the…
- Trial name
- NCT03722433
- Testing
- Vigiis 101-LAB and sequential therapy
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease
To evaluate the pharmacokinetics (PK) of SPR719, the active moiety, generated from the orally (po) administered SPR720 prodrug in a patient population with nontuberculous mycobacteria pulmonary disease (NTM-PD)
- Trial name
- NCT04553406
- Testing
- SPR720, Open-label Standard of Care
- Where
- 9 sites in United States
- Volunteers
- 2 people
- Sponsor
- Spero Therapeutics